MetaVia Inc. MTVA 深 滬
已收盤 02-06 16:00:00 美东时间
1.82
+0.090
+5.20%
華盛通- 最 高1.95
- 今 開1.81
- 成交量 22.79万股
- 最 低 1.76
- 昨 收 1.73
- 總市值 583.89万
- 52周最高 23.10
- 市盈率 靜 --
- 換手率 7.10%
- 52周最低 1.6608
- 委 比 49.97%
- 總股本 320.82万
- 歷史最高 1527900.00
- 量 比 0.48
- 振 幅 10.98%
- 歷史最低 1.6608
- 每 手 1
- 風險率 4.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Metavia Provided an Update on Its Ongoing Collaboration With Syntekabio, Leveraging Deepmatcher Platform, Confirming Strong Inflammatory And Cardiometabolic Target Engagement, Supporting Development in MASH and Potential Type 2 Diabetes
Using AI-based compound-protein interaction modeling, Syntekabio has identified key disease targets for MetaVia's oral G-protein-coupled receptor 119 (GPR119) agonist, vanoglipel (DA-1241). The analysis highlighted
02-04 21:14
What Does the Market Think About MetaVia Inc?
MetaVia Inc's (NYSE:MTVA) short interest as a percent of float has fallen 67.55...
01-19 22:00
MetaVia prices $8.1M underwritten public offering
MetaVia (NASDAQ:MTVA) on Thursday stated that it priced an underwritten public offering of common stock and Series C and D warrants for gross proceeds of about $8.1M, with underwriters granted a 45-d...
01-15 22:55
Metavia Announces The Pricing Of $8.1M Underwritten Public Offering Of 2,613,544 Shares, With 3,920,316 Series C Warrants And 3,920,316 Series D Warrants At A Combined Price Of $3.10
MetaVia Inc. (NASDAQ:MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the pricing of its underwritten public offering of shares
01-15 22:35
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
HC Wainwright & Co. Maintains Buy on MetaVia, Raises Price Target to $40
HC Wainwright & Co. analyst Andrew S. Fein maintains MetaVia (NASDAQ:MTVA) with a Buy and raises the price target from $12 to $40.
01-07 01:56
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that on ...
2025-12-22 21:31
Why Confluent Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Shares of Confluent Inc (NASDAQ:CFLT) rose sharply in pre-market trading. Inter...
2025-12-08 18:26
MetaVia Announces 1-For-11 Reverse Stock Split Of Its Common Stock, Effective December 4
MetaVia Inc. (NASDAQ:MTVA) ("MetaVia" or the "Company"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a 1-for-11 reverse stock split of its common stock, par
2025-12-02 21:47
MetaVia Q3 EPS $(0.14) Beats $(0.25) Estimate
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.25) by 43.78 percent. This is a 74.55 percent increase over losses of $(0.55) per share from the same
2025-11-06 21:41
